We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pre-Markets Mixed Following S&P 500's Fresh High, Strong Earnings
Read MoreHide Full Article
Pre-market activities are up modestly on the back of a fresh all-time high recorded by the S&P 500 on Aug 18. It took six months, from Feb 19 to Aug 18 for the S&P 500 Index to reach where it was before the pandemic. Market participants enjoyed an astonishing 54.7% rally of the broad-market index since its crash on Mar 23. However, President Trump's decision to cancel trade talks with China, which was postponed last weekend, dampened investors' spirit.
Adding pace to the recent mergers and acquisitions, Johnson & Johnson (JNJ - Free Report) has decided to takeover Momenta Pharmaceuticals Inc. for $6.5 billion in cash in order to enhance its autoimmune disease treatments portfolio. In pre-market trading, shares of Momenta are up more than 65%.
Retail giant Target Corp. (TGT - Free Report) witnessed 24.3% year-over-year growth in comparable sales, which is, strongest ever, and a 195% surge in online sales. In-store comparable sales also grew 10.9% year over year.
Quarterly adjusted earnings of $3.38 per share surpassed the Zacks Consensus Estimate of $1.64 and increased from $1.82 reported a year-ago. Revenues of $22.98 billion exceeded the Zacks Consensus Estimate of $20.24 billion and improved from the year-ago amount of $18.42 billion. For a detailed analysis of TGT earnings, click here.
Building products retailer Lowe's Companies Inc. (LOW - Free Report) reported stronger than-expected second-quarter fiscal 2020 earnings results. The coronavirus-led lockdowns enabled Americans to focus on home repairs that boosted same-store sales by 35.1%. Meanwhile, online sales soared 135% year over year.
Quarterly adjusted earnings per share of $3.75, beat the Zacks Consensus Estimate of $3.03. Year-ago earnings were $2.15 per share. Revenues of $27.30 billion exceeded the Zacks Consensus Estimate of $24.71 billion and increased from $20.99 billion in the prior-year quarter. For a detailed discussion on LOW's earnings, click here.
Meanwhile, discount store retailer The TJX Companies Inc. (TJX - Free Report) reported disappointing earnings for second-quarter fiscal 2021. Adjusted loss per share of 18 cents was wider-than the Zacks Consensus Estimate of a loss of 8 cents. It had reported earnings of 62 cents per share a year earlier. Revenues of $6.67 billion missed the Zacks Consensus Estimate of $6.95 billion and deteriorated from the year-ago figure of $9.78 billion. Moreover, open-only comparable store sales declined 3% year over year. For knowing more on TJX's earnings, click here.
Semiconductor giant Analog Devices Inc. (ADI - Free Report) reported better-than-expected third quarter fiscal 2020 earnings results. Adjusted earnings of $1.36 per share outpaced the Zacks Consensus Estimate of $1.33 per share and increased from $1.26 reported a year-ago. Revenues of $1.46 billion were slightly above the Zacks Consensus Estimate of $1.45 billion. However, the top line declined from $1.48 billion reported a year-ago. To get more information on ADI's earnings, click here.
After the closing bell today, semiconductor behemoth NVIDIA Corp. (NVDA - Free Report) , tech major Synopsys Inc. (SNPS - Free Report) , retailer L Brands Inc. and manufacturing bigwig Nordson Corp. (NDSN - Free Report) are slated to report their earnings results.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Pre-Markets Mixed Following S&P 500's Fresh High, Strong Earnings
Pre-market activities are up modestly on the back of a fresh all-time high recorded by the S&P 500 on Aug 18. It took six months, from Feb 19 to Aug 18 for the S&P 500 Index to reach where it was before the pandemic. Market participants enjoyed an astonishing 54.7% rally of the broad-market index since its crash on Mar 23. However, President Trump's decision to cancel trade talks with China, which was postponed last weekend, dampened investors' spirit.
Adding pace to the recent mergers and acquisitions, Johnson & Johnson (JNJ - Free Report) has decided to takeover Momenta Pharmaceuticals Inc. for $6.5 billion in cash in order to enhance its autoimmune disease treatments portfolio. In pre-market trading, shares of Momenta are up more than 65%.
Retail giant Target Corp. (TGT - Free Report) witnessed 24.3% year-over-year growth in comparable sales, which is, strongest ever, and a 195% surge in online sales. In-store comparable sales also grew 10.9% year over year.
Quarterly adjusted earnings of $3.38 per share surpassed the Zacks Consensus Estimate of $1.64 and increased from $1.82 reported a year-ago. Revenues of $22.98 billion exceeded the Zacks Consensus Estimate of $20.24 billion and improved from the year-ago amount of $18.42 billion. For a detailed analysis of TGT earnings, click here.
Building products retailer Lowe's Companies Inc. (LOW - Free Report) reported stronger than-expected second-quarter fiscal 2020 earnings results. The coronavirus-led lockdowns enabled Americans to focus on home repairs that boosted same-store sales by 35.1%. Meanwhile, online sales soared 135% year over year.
Quarterly adjusted earnings per share of $3.75, beat the Zacks Consensus Estimate of $3.03. Year-ago earnings were $2.15 per share. Revenues of $27.30 billion exceeded the Zacks Consensus Estimate of $24.71 billion and increased from $20.99 billion in the prior-year quarter. For a detailed discussion on LOW's earnings, click here.
Meanwhile, discount store retailer The TJX Companies Inc. (TJX - Free Report) reported disappointing earnings for second-quarter fiscal 2021. Adjusted loss per share of 18 cents was wider-than the Zacks Consensus Estimate of a loss of 8 cents. It had reported earnings of 62 cents per share a year earlier. Revenues of $6.67 billion missed the Zacks Consensus Estimate of $6.95 billion and deteriorated from the year-ago figure of $9.78 billion. Moreover, open-only comparable store sales declined 3% year over year. For knowing more on TJX's earnings, click here.
Semiconductor giant Analog Devices Inc. (ADI - Free Report) reported better-than-expected third quarter fiscal 2020 earnings results. Adjusted earnings of $1.36 per share outpaced the Zacks Consensus Estimate of $1.33 per share and increased from $1.26 reported a year-ago. Revenues of $1.46 billion were slightly above the Zacks Consensus Estimate of $1.45 billion. However, the top line declined from $1.48 billion reported a year-ago. To get more information on ADI's earnings, click here.
After the closing bell today, semiconductor behemoth NVIDIA Corp. (NVDA - Free Report) , tech major Synopsys Inc. (SNPS - Free Report) , retailer L Brands Inc. and manufacturing bigwig Nordson Corp. (NDSN - Free Report) are slated to report their earnings results.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>